Background. For stage IV melanoma, systemic medical therapy (SMT) is used most frequently; surgery is considered an adjunct in selected patients. We retrospectively compared survival after surgery with or without SMT versus SMT alone for melanoma patients developing distant metastases while enrolled in the first Multicenter Selective Lymphadenectomy Trial. Methods. Patients were randomized to wide excision and sentinel node biopsy, or wide excision and nodal observation. We evaluated recurrence site, therapy (selected by treating clinician), and survival after stage IV diagnosis. Results. Of 291 patients with complete data for stage IV recurrence, 161 (55 %) underwent surgery with or without SMT. Median survival was 15.8 versus 6.9 months, and 4-year survival was 20.8 versus 7.0 % for patients receiving surgery with or without SMT versus SMT alone (p \ 0.0001; hazard ratio 0.406). Surgery with or without SMT conferred a survival advantage for patients with M1a (median [ 60 months vs. 12.4 months; 4-year survival 69.3 % vs. 0; p = 0.0106), M1b (median 17.9 vs. 9.1 months; 4-year survival 24.1 vs. 14.3 %; p = 0.1143), and M1c (median 15.0 vs. 6.3 months; 4-year survival 10.5 vs. 4.6 %; p = 0.0001) disease. Patients with multiple metastases treated surgically had a survival advantage, and number of operations did not reduce survival in the 67 patients (42 %) who had multiple surgeries for distant melanoma. Conclusions. Our findings suggest that over half of stage IV patients are candidates for resection and exhibit
distant metastases while enrolled in the first Multicenter Selective Lymphadenectomy Trial. Methods. Patients were randomized to wide excision and sentinel node biopsy, or wide excision and nodal observation. We evaluated recurrence site, therapy (selected by treating clinician), and survival after stage IV diagnosis. Results. Of 291 patients with complete data for stage IV recurrence, 161 (55 %) underwent surgery with or without SMT. Median survival was 15.8 versus 6.9 months, and 4-year survival was 20.8 versus 7.0 % for patients receiving surgery with or without SMT versus SMT alone (p \ 0.0001; hazard ratio 0.406). Surgery with or without SMT conferred a survival advantage for patients with M1a (median [ 60 months vs. 12.4 months; 4-year survival 69.3 % vs. 0; p = 0.0106), M1b (median 17.9 vs. 9.1 months; 4-year survival 24.1 vs. 14.3 %; p = 0.1143), and M1c (median 15.0 vs. 6.3 months; 4-year survival 10.5 vs. 4.6 %; p = 0.0001) disease. Patients with multiple metastases treated surgically had a survival advantage, and number of operations did not reduce survival in the 67 patients (42 %) who had multiple surgeries for distant melanoma. Conclusions. Our findings suggest that over half of stage IV patients are candidates for resection and exhibit improved survival over patients receiving SMT alone, regardless of site and number of metastases. We have begun a multicenter randomized phase III trial comparing surgery versus SMT as initial treatment for resectable distant melanoma.
Melanoma has become one of the most expensive cancers to diagnose, treat, and follow. 1 Most of this expense represents the management of distant metastatic disease. Many medical oncologists believe that once melanoma has spread through the bloodstream to a distant site, surgery is not useful because patients already have clinically relevant circulating tumor cells and subclinical occult metastases. 2, 3 Thus, systemic medical therapy (SMT) remains the mainstay of management for stage IV disease. 4, 5 However, a meta-analysis by Korn et al. showed no significant outcome difference for different types of medical therapy. 6 Although promising data from recent trials of targeted therapy challenge the findings of Korn's group, currently there is no standard approach to treatment of distant melanoma or consensus on the role of surgery. [7] [8] [9] The results of several previous studies suggest that surgical resection of distant melanoma should be undertaken whenever feasible. Data from small, singleinstitution prospective series indicate that 5-year survival is possible in 15-28 % of patients with distant metastases that can be completely resected. [10] [11] [12] [13] [14] [15] [16] [17] The Southwestern Oncology Group's small multicenter phase II study of surgery for stage IV melanoma found a median survival of 21 months and an estimated 4-year survival of 31 %; 62 (83.8 %) of 74 candidates for the study had disease that could be completely resected, and 48 % had visceral metastases. 18 These multicenter trial data confirm single-center reports of the effectiveness of surgery alone in patients with stage IV melanoma. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Serial surgical operations for metachronous metastases can control disease, but sequential combined approaches that use surgery and medical therapy have not been well explored. In the present study, we hypothesized that when melanoma recurs at a distant site, complete surgical resection is the best treatment option when feasible and may offer an opportunity for cure as compared to SMT alone. We examined this hypothesis by comparing the treatment and overall survival of patients who developed distant metastases while enrolled in the first Multicenter Selective Lymphadenectomy Trial [MSLT-I; National Institutes of Health (NIH) Clinical Trials Identifier: NCT00275496], an international phase III trial for patients with clinically localized cutaneous melanoma. 23 
PATIENTS AND METHODS

MSLT-I Design
As previously reported, MSLT-I randomly assigned patients with primary cutaneous melanoma to two treatment arms: wide excision and sentinel node biopsy, with immediate complete lymphadenectomy for histopathologic evidence of sentinel node metastasis; or wide excision and postoperative observation of the regional nodal basin, with delayed complete lymphadenectomy on clinical evidence of regional node metastasis. 23 Patients with tumor-positive sentinel nodes or clinical evidence of nodal involvement during follow-up could receive adjuvant systemic therapy. 
Design of the Retrospective Study Based on MSLT-I Data
The MSLT-I database was queried for patients who developed stage IV recurrence. We excluded patients who developed locoregional recurrence without concurrent distant disease, patients who did not receive treatment for stage IV melanoma, and patients whose stage IV treatment data were missing. Treatment was categorized as surgery alone, surgery followed by SMT, SMT followed by surgery, or SMT alone. SMT was categorized as chemotherapy, biochemotherapy, biotherapy, immunotherapy, radiotherapy, or treatment with an unspecified systemic agent. Although not systemic therapy, radiation was included in this group as a nonsurgical treatment for patients with stage IV melanoma recurrence.
The primary endpoint was overall survival after diagnosis of stage IV recurrence. Distant disease-free interval (DDFI) was the interval between initial diagnosis of melanoma and first stage IV recurrence. The number of distant metastases and the number of distant recurrence organ sites at the first stage IV recurrence were evaluated. Progressionfree survival (PFS) was the interval between surgical treatment for initial stage IV recurrence and diagnosis of subsequent recurrence.
Survival estimates were evaluated by the Kaplan-Meier method. Univariate and multivariate analyses were performed. v 2 tests were used to evaluate the relationship between DDFI quartiles and surgery. The p values and hazard ratios for survival were calculated by the Cox proportional hazard models. All reported p values are two sided, with a value of less than 0.05 considered to indicate statistical significance. Analyses were performed by SAS software, version 9.1.
RESULTS
Multicenter Trial Cohort
Follow-up data were available for 1,970 patients from MSLT-I: 397 (20.1 %) of 1,970 patients developed stage IV recurrence; 291 of the 397 (73.3 %) had detailed records of treatment for stage IV recurrence.
Demographics for the 291 patients who were treated for distant melanoma metastases revealed that 63 % were male and 68 % were 60 years of age or younger. Nearly all patients were Caucasian. Most patients had high-risk primary melanomas: Clark level IV (63 %) and Breslow thickness 1.2-3.5 mm (65 %) ( Table 1) . Of the 291 patients, 32 (10 %) had M1a disease, 49 (17 %) had M1b disease, and 210 (73 %) had M1c disease. Median survival and 4-year overall survival rate of all patients treated for stage IV disease were 11.6 months and 14.4 %, respectively. The 106 patients without treatment information had a median survival of 3.5 months and 4-year overall survival rate of 13.6 %.
Stage IV recurrence involved only one organ in 242 patients (83 %), two organs in 35 patients (12 %), and three or more separate organs in 14 patients (5 %). Of these, 226 patients (78 %) had only one solitary distant metastasis, 43 (15 %) had two solitary metastases, and 22 (7 %) had three or more solitary metastases.
Treatment Profile
Of patients treated for stage IV recurrence, 43 (15 %) received surgery alone, 85 (29 %) received surgery followed by SMT, 33 (11 %) received SMT followed by surgery, and 130 (45 %) received SMT alone (Table 1) . Of the 248 patients whose treatment included SMT, 138 (44 %) received chemo/biochemotherapy, 80 (32 %) received radiation, 18 (7 %) received immunotherapy, and 8 (3 %) received biotherapy; in 4 patients (2 %), the details of SMT were not available. Among patients who received SMT before surgery, median interval between the two types of treatment was 241 days. The most frequent type of SMT administered before surgery was chemo/biochemotherapy (n = 24, 73 %).
Surgery was used for treatment of recurrence in 161 patients (55 %); of these 161 patients, 67 (42 %) had more than one operation. As expected, use of surgery was inversely related to the number of distant organ sites of recurrence; surgical resection was all or part of the treatment plan for 60, 40, and 21 % patients with 1, 2, and C3 organ sites of recurrence, respectively (p = 0.0031). Corresponding nonsurgical therapy rates were 40, 60, and 79 %, respectively, for patients with the same number of tumor-involved organ sites (Table 2) . Surgical complication rates for stage IV recurrences were not available. In the 161 patients treated surgically there were 4 deaths (2.5 %) within 30 days after surgery.
Survival and Recurrence Outcomes
Median survival after stage IV diagnosis was 15.8 months for patients who received surgery at any point during treatment for their distant metastases and only SMT systemic medical therapy 6.9 months for patients who received SMT alone (p \ 0.0001) (Fig. 1a) . When the surgery group was further evaluated, median survival was 22.1 months for patients who received surgery alone (p \ 0.0001), 17.1 months for patients who received SMT followed by surgery (p \ 0.0001), and 14.7 months for those who underwent surgery followed by SMT (p \ 0.0001). Fouryear survival was 20.8 % for all patients with stage IV recurrence treated surgically and 45.7, 18.2, and 12.3 % for the respective surgical subgroups. Four-year survival for patients treated without surgery was only 7 %. Order of therapy did not influence survival for patients treated with systemic therapy and surgery (p = 0.2401) (Fig. 1b) . The median interval between initial diagnosis of melanoma and development of stage IV recurrence (DDFI) was 29.7 months. Survival after stage IV recurrence was associated with a longer DDFI (C12 months) for all patients (p = 0.0001). Patients with a longer DDFI were more likely to undergo surgical treatment (p = 0.0296). There was a difference in survival for patients who received surgery after a short (\12 month) versus long (C12 month) DDFI (p = 0.0093), but surgery was associated with improved survival for patients with both short and long DDFI. Patients who developed distant recurrence after at least 12 months had improved median survival (17.8 vs. 7.4 months) if they were treated with surgery versus SMT alone (p \ 0.0001) (Fig. 2a) . Patients who recurred in less than 12 months also had improved median survival (9.3 vs. 5.4 months) when treated with surgery versus SMT alone (p = 0.0326) (Fig. 2b) . Median PFS and 4-year rate of PFS after surgical treatment for stage IV recurrence were 7.6 months and 18.0 %, respectively.
Surgical treatment was associated with improved survival for any M category. Patients with M1a metastases had a median survival of [60 months with surgery with or without SMT, versus 12.4 months with SMT alone (p = 0.0106). Four-year survival was 69.3 % for surgical patients and 0.0 % for nonsurgical patients (Fig. 3a) . For the M1b group, median survival was 17.9 months with surgery with or without SMT versus 9.1 months with SMT alone (p = 0.1143). Four-year survival was 24.1 % for surgical patients and 14.3 % for nonsurgical patients (Fig. 3b) . For the M1c group, median survival was 15.0 months with surgery with or without SMT, versus 6.3 months with SMT alone (p \ 0.0001). Four-year survival was 10.5 % for surgical patients and 4.6 % for nonsurgical patients (Fig. 3c) .
In an effort to minimize selection bias, patients with similar disease status were compared by treatment received. This included comparisons based on number of individual metastases as well as number of organ systems affected. Surgical treatment tended to be associated with improved survival regardless of the number of separate distant metastases. Median survival for patients receiving surgery with or without SMT versus SMT alone was 16.3 versus 7.5 months in patients with a single metastasis (p \ 0.0001) (Fig. 4a) , 17.1 versus 6.9 months in patients with two metastases (p = 0.0364) (Fig. 4b) , and 13.9 months versus 5.2 months in patients with three metastases (p = 0.0850) (Fig. 4c) . Interestingly, patients who had multiple operations to treat their metastases had a 21.1-month median survival and a 25.0 % 4-year survival rate, as compared with 13 months and 18 %, respectively, for patients receiving only one operation (p = 0.0218). Survival decreased significantly for surgical patients as the number of organ sites of recurrence increased to two (p = 0.0041) or to three or more (p = 0.0001). Median survival for patients receiving surgery was 17.6 months with one organ site of distant recurrence, 13.4 months with two organ sites of recurrence, and 4.5 months with 3 or more organ sites of recurrence. By comparison, median survival for patients receiving SMT alone was only 7.5, 6.6, and 4.8 months, respectively (Table 2) . Factors significant in univariate analysis were used as a basis for comparing treatment groups with multivariate analysis, which revealed that treatment modality and M stage showed significance for survival. Patients treated with surgery with or without SMT had better survival than patients treated only with SMT (p \ 0.0001, hazard ratio = 0.463). Patients with M1a disease showed improved survival when treated surgically (p \ 0.0001). Age (p = 0.2465), sex (p = 0.0638), and previously diagnosed stage III disease (p = 0.0532) (with or without palpable lymph nodes) did not show significance for survival on multivariate analysis. A DDFI of C12 months was associated with improved survival. A lower number of organ sites of metastases was associated with improved survival; however, the number of individual metastases was not a significant prognostic factor on multivariate analysis (Table 3) .
DISCUSSION
The strength of this study is its size. To our knowledge, this represents the largest evaluation of multicenter prospective data from early-stage melanoma patients who were longitudinally followed up and treated for melanoma metastatic to skin, soft tissue, lung, or visceral organs. Our findings indicate a survival advantage for a surgical approach, even in patients with high-risk visceral metastases or multiple metastases that may require multiple operations for complete resection. Clearly not all patients with distant melanoma are candidates for resection as a result of extensive tumor burden or poor performance status, but our data suggest that at least 55 % of stage IV patients may be eligible to undergo surgery as part of their treatment plan. We therefore believe that the surgeon should play an integral role in evaluation and treatment planning for all patients with stage IV recurrence of melanoma.
One potential therapeutic advantage of resection is that it may delay disease progression by interrupting the metastatic cascade associated with hematogenous seeding of cells to other sites. 24 In addition, it immediately reduces tumor burden and thereby decreases tumor-induced immune suppression. 25 This is particularly important for tumor masses larger than 2 cm, which may prove difficult to completely eradicate with systemic therapy. 26 Finally, metastasectomy may enhance the patient's endogenous immune defenses or response to adjuvant immunotherapy and thus maintain a complete clinical remission. 27 Although immunologic data after diagnosis of distant recurrence were not available for patients in our study, John Wayne Cancer Institute investigators have previously reported a direct correlation between specific endogenous antitumor antibody immune responses and postoperative survival of patients with stage IV melanoma. 27 Surgery for distant metastases has been improved by development of more advanced imaging techniques that can detect lesions as small as 5-10 mm. 28 These techniques can differentiate patients with multiple versus limited metastases, allowing surgeons to better judge the extent of disease and plan the operative procedure necessary for complete resection. In addition, modern advances in anesthesia, surgical techniques and supportive care have reduced operative mortality from multiple metastasectomy to below 1-2 %, with a corresponding reduction in morbidity. 29 Finally, shorter postsurgical hospitalizations have decreased the total costs of cancer surgery, often below the costs of newer chemotherapeutic and biologic cancer therapies such as a 4-cycle course of ipilimumab, which costs approximately $120,000.
Our study was limited by a possible selection bias with respect to choice of therapy for patients at the time of stage IV diagnosis. Patients undergoing surgery for distant melanoma tend to have less extensive disease, whereas patients receiving SMT alone might be more likely to have multiple tumors. We attempted to control for this bias by comparing surgical and nonsurgical cohorts on the basis of M-stage, number of metastases, number of sites with distant metastases, and DDFI. Our study was also limited by its retrospective nature. Although the data was drawn from a carefully controlled phase III trial, the management of stage IV recurrence was not dictated or standardized in MSLT-I. We had access to recurrence dates, treatment dates, and treatment types, but not to treatment intent or treatment response. Thus, it was not possible to determine which patients underwent debulking versus curative resection, or which patients had stable versus progressive disease after SMT. Although we knew the interval between SMT and surgery, we could not determine whether SMT was administered to downstage disease before surgery, as a primary intervention instead of surgery for resectable disease, or as a palliative measure for symptom control. We also could not determine dosing duration, side-effects, or complications of SMT.
Despite the limitations of our study, the multicenter data offer impressive evidence that inclusion of surgery in the treatment plan for stage IV recurrence confers a survival advantage and the only chance for long-term survival and cure. Single-center retrospective studies also demonstrate prolonged survival after surgery, as do findings of the prospective SWOG study. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 26, 29, 30 Our median overall survival and 4-year overall survival rate (15.8 months and 20.8 %, respectively) compare favorably with SWOG data (median overall survival, 21 months; 4-year overall survival, 31 %) and are far superior to data from Korn's meta-analysis of over 2,000 patients undergoing systemic therapy for stage IV disease (median overall survival, 6.2 months; 1-year overall survival, 25.5 %). 6, 18 Further evidence to support the use of surgery for stage IV melanoma is found in the international MMAIT-IV trial (NIH Clinical Trials Identifier: NCT00052156). In this prospective randomized trial, 496 patients who had undergone complete resection of stage IV melanoma were treated adjuvantly with two types of immunotherapy. Estimated 5-year survival for the study population was 42.3 %. This trial was terminated early by the Data Monitoring Safety Board on the basis of a low probability of showing superiority of either arm. 31 The optimal approach to distant recurrent melanoma will likely be a combination of surgery and immune-based systemic therapies. As novel targeted agents continue to demonstrate encouraging results in phase I-III trials, more patients will become candidates for neoadjuvant or postoperative treatment regimens. [7] [8] [9] 32, 33 Indeed, many of the new systemic agents can demonstrate reduced disease progression but do not yet create high complete response rates, leaving significant residual tumor. [7] [8] [9] The timing of surgery versus systemic treatments thus will become particularly critical, which is why we are examining the efficacy of initial surgical versus systemic treatment for resectable stage IV melanoma in a prospective phase III international trial (NIH Clinical Trials Identifier: NCT01013623). As shown in the supplementary figure, patients with B6 metastases in B3 organ sites are randomized to surgery with or without bacillus CalmetteGuerin adjuvant immunotherapy, or to SMT. The primary endpoint is overall survival; secondary endpoints are time to progression of target lesions or development of new lesions. This trial will attempt to confirm the high survival rate after metastasectomy and establish the indications for surgical resection in treatment of stage IV melanoma.
